Repare Therapeutics/RPTX

$6.62

-0.6%
-
1D1W1MYTD1YMAX

About Repare Therapeutics

Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.

Ticker

RPTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Lloyd Segal

Employees

180

Headquarters

St-laurent, Canada

RPTX Metrics

BasicAdvanced
$278.9M
Market cap
-
P/E ratio
-$2.32
EPS
0.59
Beta
-
Dividend rate

What the Analysts think about RPTX

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
164.35% upside
High $29.00
Low $8.00
$6.62
Current price
$17.50
Average price target

RPTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-895.23% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$2.1M
-93.05%
Net income
$-18.8M
57.98%
Profit margin
-895.23%
2,172.16%

RPTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 47.6%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.75
-$0.83
-$0.28
-$0.45
-
Expected
-$0.72
-$0.81
-$0.78
-$0.86
-$0.46
Surprise
3.92%
2.65%
-64.1%
-47.6%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Repare Therapeutics stock

Buy or sell Repare Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing